Welcome to our dedicated page for OmniAb news (Ticker: OABI), a resource for investors and traders seeking the latest updates and insights on OmniAb stock.
OmniAb, Inc. reports developments tied to its antibody discovery technology platform, partner pipeline and licensing model. The company licenses discovery research technology to pharmaceutical, biotechnology and academic partners, using engineered transgenic animals, Biological Intelligence™, computational antigen design, immunization methods, high-throughput single B-cell screening and sequencing-data mining to identify human antibody and target-binding protein candidates.
Recurring news includes quarterly financial results, partner program updates, new license agreements, milestone and royalty revenue, and technology launches such as OmniUltra™ and the xPloration® partner access program. Company updates also cover clinical and commercial progress of OmniAb-derived partnered programs, investor conference participation and corporate presentations focused on antibody discovery applications.
OmniAb (NASDAQ: OABI) announced management participation in three investor conferences in November 2025. Key events:
- Truist Securities BioPharma Symposium — November 6, Lotte New York Palace Hotel; Matt Foehr, CEO, will hold one-on-one investor meetings.
- Stifel Healthcare Conference — November 11-13, Lotte New York Palace Hotel; Kurt Gustafson, CFO, will hold one-on-one investor meetings on November 12.
- Jefferies Global Healthcare Conference — London — November 17-20, Waldorf Hilton; Matt Foehr will present a corporate overview on November 19 at 8:00 a.m. GMT and hold meetings on November 18-19.
The schedule highlights management access to investors via presentations and one-on-one meetings across U.S. and London industry conferences.
OmniAb (NASDAQ: OABI) will report third quarter 2025 financial results for the three and nine months ended September 30, 2025 after U.S. market close on Tuesday, November 4, 2025. The company will host a conference call and webcast the same day beginning at 4:30 p.m. Eastern / 1:30 p.m. Pacific to discuss results and business updates.
Participants can join by phone (U.S. dial-in (800) 549 8228; international (646) 564 8277; Conference ID 92631). A live webcast and replay with slides will be available via the company’s webcast link.
OmniAb (NASDAQ: OABI) announced its participation in the upcoming H.C. Wainwright 27th Annual Global Investment Conference, scheduled for September 8-10, 2025, at the Lotte New York Palace Hotel. The company's management team will be available for one-on-one meetings with registered investors on September 9, 2025.
Interested investors can schedule meetings through their H.C. Wainwright representative or by emailing meetings@hcwco.com.
OmniAb (NASDAQ: OABI) has announced a private placement to raise approximately $30 million through the sale of 21,254,106 shares of common stock. The shares will be priced at $1.40 per share, with officer and director participants paying $1.85 per share.
The placement, expected to close around August 26, 2025, includes participation from top-tier new and existing investors, along with company officers and directors. Leerink Partners is serving as the sole placement agent. The proceeds will be used for general corporate purposes, and OmniAb will file a registration statement with the SEC for the resale of these shares.
OmniAb (NASDAQ: OABI) reported Q2 2025 financial results, showing revenue of $3.9 million, down from $7.6 million in Q2 2024. The company posted a net loss of $15.9 million ($0.15 per share). Despite lower revenue, OmniAb achieved significant business milestones, reaching 100 active partners and 381 active programs, including 32 OmniAb-derived programs in clinical development or commercialization.
The company launched the xPloration® Partner Access Program and entered six new license agreements. Notable highlights include partner Immunovant initiating Phase 3 trials for IMVT-1402, and Johnson & Johnson's JNJ-5322 showing 100% overall response rate in initial Phase 1 results. OmniAb maintains its 2025 revenue guidance of $20-25 million and expects operating expenses of $85-90 million.
OmniAb (NASDAQ: OABI) has scheduled its second quarter 2025 financial results announcement for August 6, 2025, after U.S. market close. The company will host a conference call and webcast at 4:30 p.m. Eastern time to discuss the results and provide business updates.
Interested parties can access the call via phone using U.S. number (800) 549 8228 or international number (289) 819 1520 with Conference ID 93102. A live webcast with slides will also be available for viewing.
OmniAb (NASDAQ: OABI) showcased its innovative xPloration platform at the 21st Annual PEGS Boston Summit. The platform is a high-throughput single B-cell screening technology that leverages machine learning and AI for antibody discovery. xPloration processes millions of single B-cells and identifies thousands of antibody variants within hours, screening 10 times more single cells per day than other spatial separation techniques.
Key features include a laser-based "touchless" cell recovery process, short 1.5-hour instrument run times, and AI-assisted image analysis. The platform supports various assay formats, including multiplex cell surface binding and cross-blocking assays. OmniAb has launched a Partner Access Program, allowing current partners to purchase the instrument for their laboratories.
OmniAb (NASDAQ: OABI) has launched the xPloration Partner Access Program, allowing current partners to purchase their proprietary high-throughput single B-cell screening platform. The xPloration instrument leverages machine learning and AI to enhance antibody discovery and development capabilities.
The platform features custom chips with 1.5 million microcapillaries for B-cell isolation and completes instrument runs in approximately 1.5 hours. Key advantages include superior processing speed, exceptional hit recovery, and enhanced discovery efficiency through laser-based recovery and advanced functional screening assays. The technology will be showcased at the 21st Annual PEGS Boston Summit (May 12-16, 2025) through presentations by Dr. Bob Chen and Dr. John Kenney.
OmniAb (NASDAQ: OABI) has announced its participation in five upcoming investor conferences in May and June 2025. The company's management will attend:
- H.C. Wainwright 1st Annual Royalty Company Virtual Conference (May 13)
- H.C. Wainwright 3rd Annual BioConnect Investor Conference at Nasdaq (May 20)
- RBC Capital Markets Global Healthcare Conference (May 20-21)
- Benchmark 2025 Healthcare House Call Virtual Conference (May 29)
- Jefferies Global Healthcare Conference (June 3-5)
Management will participate in fireside chats, panel discussions, and one-on-one meetings with investors across these events.